[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-colon-cancer-breast-cancer-lymphoma-chronic-lymphoma-leukemia-multiple-myeloma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-colon-cancer-breast-cancer-lymphoma-chronic-lymphoma-leukemia-multiple-myeloma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,57,94,123,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100605376","sbu-reset-relaxation-stress-reduction-and-epigenetics-trial-in-cancer-survivors-100605376",false,"NCT07161713","SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors","Pilot Study of a Social\u002FBehavioral Intervention on Cancer Survivors, Evaluating the Effect of Mind Body Interventions on Patient Reported Outcomes, Inflammation and Epigenetics.","RESET","Inclusion Criteria:\n\n* Adults over 18 years old\n* Primary diagnosis: Lung Cancer, Colon Cancer and Non-Hodgkin's lymphoma (NHL)\n* Six months post cancer-directed treatment (chemotherapy, targeted and immunotherapy). Patients with active disease (e.g. metastatic colorectal cancer) who are not receiving any cancer-directed treatment are eligible.\n* Able to provide a saliva sample\n* Gives informed consent and agrees to be randomly assigned\n* Able to complete the questionnaire(s) in English.\n\nExclusion Criteria:\n\n* Adults with primary anal and\u002For primary rectal cancer.\n* Adult cancer survivors who are currently on an active treatment regimen.\n* Oral or any pathological conditions that can limit the ability to produce saliva.\n* Unable to participate in full length study period and follow up thereafter.\n* Is pregnant or plan to become pregnant during the study period.\n* Currently practicing yoga or SMART\n* Those on corticosteroid therapy.\n* Documented fall or syncope within the last 6 months","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cancer survivors can experience health issues that cause chronic illness and lower quality of life. Yoga is a well-known holistic approach to health and overall well-being. Mindfulness has many benefits, including improved focus and less stress. This study aims to evaluate if yoga and\u002For mindfulness has a positive effect on cancer survivors social, emotional and physical well-being as well as their epigenetics. Epigenetics is how the environment can effect your genes; not by changing our DNA, but by turning genes on or off.",[27,28,29],"Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)","Cancer Survivors","Cancer Survivorship",[31,32,33,34,35,36,37,38,39,40,41,42,43],"stony brook","survivor","yoga","mindfulness-based stress reduction","holistic","stress management","cancer survivor","long island","mindfulness","cancer","EORTC","questionnaires","surveys","RECRUITING","2026-06-26",{"date":47,"type":48},"2026-06-30","ACTUAL",{"date":50,"type":48},"2025-09-17",{"date":52,"type":21},"2027-09-30",{"name":54,"class":55},"Barbara Nemesure","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":22,"phases":67,"briefSummary":68,"conditions":69,"keywords":76,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":56},"100615261","survivors-uniting-for-remote-guided-exercise-100615261","NCT07290309","Survivors Uniting for Remote Guided Exercise","Efficacy of a Group-based Videoconference Intervention to Increase Physical Activity in Cancer Survivors","SURGE","Inclusion Criteria:\n\n* Able to speak\u002Fread English,\n* Diagnosed with any type of cancer within the last 5 years\n* Completed primary or adjuvant treatment (i.e., chemotherapy, radiation therapy, surgery) with no planned treatment within the next nine months. This does not include long-term or chronic therapies such as anti-hormone or targeted therapies (e.g., aromatase inhibitor, androgen deprivation therapy, immunotherapies)\n\nExclusion Criteria:\n\n* Existing participation in ≥150 minutes per week of at least moderate intensity aerobic exercise\n* Known contraindications for non-medically supervised moderate or greater intensity exercise (e.g., uncontrolled hypertension, inability to walk without an assistive device)\n* Current or planned participation in another structured program or intervention intended to encourage participation in exercise or physical activity.",{"count":66,"type":21},300,[24],"The goal of this research study is to look at how live, online group exercise compares to recorded videos for helping increase physical activity levels, improve physical fitness and quality of life, and reduce loneliness among those living with and beyond cancer. The following aims have been established for this study:\n\n* Aim 1: Examine the effect of a group-based videoconference physical activity (PA) intervention on moderate to vigorous physical activity \\[MVPA\\] (i.e., aerobic and resistance exercise).\n* Aim 2: Examine the effect of the intervention on additional health-related outcomes including physical fitness (i.e., aerobic endurance, muscular strength), and quality of life at both timepoints.\n* Aim 3: Explore potential mediators and moderators of intervention effects. We will examine mediators (e.g., self-efficacy, outcome expectations, group cohesion) and moderators (e.g., age, cancer stage, neighborhood walkability) of the intervention on MVPA.\n* Exploratory Aim: Determine whether a group-based videoconference PA intervention reduces loneliness among cancer survivors.\n\nResearchers will randomize participants into one of two guided exercise groups that are 12-weeks long in duration. Participants will be asked to complete online fitness assessments and surveys as well as wear a physical activity monitor device and watch a few times throughout the study. The whole study is 9-months long in duration with a 6-month free-living period where no study activities will take place.",[70,27,71,72,73,74,75],"Cancer","Physical Activity","Physical Activity Behavior","Cancer (With or Without Metastasis)","Cancer - Chronic Lymphocytic Leukemia","Cancer - Ovarian",[77,78,79,80,81,82,83,84],"Exercise oncology","Physical activity for cancer survivors","Group based exercise","Virtual exercise","physical activity","exercise","remote study","Cancer survivors","2026-03-27",{"date":87,"type":48},"2026-03-31",{"date":89,"type":48},"2026-02-06",{"date":91,"type":21},"2030-03-01",{"name":93,"class":55},"Colorado State University",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":56},"100613611","use-of-preoperative-postbiotic-supplementation-in-colorectal-cancer-surgery-100613611","NCT07268846","Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery","Randomized Clinical Trial on the Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery","POSBIO-CRC","Inclusion Criteria:\n\n* Individuals diagnosed with malignant neoplasm of the large intestine, specifically adenocarcinoma.\n* Patients over 18 years of age, of both sexes.\n* Patients who agree to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Emergency or urgent surgeries.\n* Cytoreductive surgeries involving intraoperative intraperitoneal chemotherapy.\n* Extended surgeries for the treatment of recurrent tumors.",{"count":103,"type":21},164,[24],"The treatment of colorectal cancer, in the absence of metastases, is primarily based on surgical removal. Colorectal surgery, which involves resecting part of the intestine and restoring intestinal continuity, carries a risk of complications. This study aims to evaluate whether oral supplementation with a postbiotic at a dose of 900 mg for 7 days prior to surgery reduces the rate of postoperative complications.",[27],[108,109,110,111,112,113],"Colorectal cancer surgery","Postbiotic","colorectal cancer","intestinal microbiota","nutritional intervention","inflammation","2025-12-04",{"date":116,"type":48},"2025-12-08",{"date":118,"type":48},"2025-06-01",{"date":120,"type":21},"2027-06-01",{"name":122,"class":55},"AC Camargo Cancer Center",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":132,"studyType":133,"phases":4,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100608238","immune-adverse-events-registry-in-onco-hematologic-patients-treated-with-immunotherapy-100608238","NCT07198958","Immune Adverse Events Registry in Onco-Hematologic Patients Treated With Immunotherapy","MITOX","Inclusion Criteria:\n\n* Any male or female patient (≥18 years old) with diagnosis of solid or hematologic tumor scheduled to begin immunotherapy treatment (prospective)\n* Any male or female patient (≥18 years old) with diagnosis of solid or hematologic tumor already in treatment with immunotherapy with development of irAEs (retro\u002Fprospective)\n* Any male or female patient (≥18 years old) with diagnosis of solid or hematologic neoplasm previously treated with immunotherapy and history of irAEs (retrospective)\n* Patients able to understand and sing an informed consent form (prospective group)\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years of age\n* Patients with uncertain diagnosis of solid or hematologic tumor\n* Patients not eligible for any clinical reason for immunotherapy\n* Patients unable to understand or sign an informed consent form",{"count":131,"type":21},500,"20 Years","OBSERVATIONAL","Immunotherapy is a therapeutic strategy aimed at inducing the immune system to identify and combat cancer cells and, alongside the evident clinical success observed in many patients, a specific toxicity profile has emerged, associated with the modulation of the immune system achieved with this type of drugs, known as Immune-Related Adverse Events (irAEs). irAEs encompass a highly heterogeneous spectrum of autoimmune manifestations that can potentially involve any organ or system, occurring in \\~ 80% of patients treated with anti-CTLA-4 agents and in \\~ 60-70% of patients treated with PD-1\u002FPD-L1 inhibitors. However, severe (grade 3-4) irAEs affect only \\~ 15% of patients treated with CTLA-4 inhibitors and \\~ 5-10% of patients receiving anti-PD-1\u002FPD-L1 agents, with a mortality rate ranging from 0.36% to 1.23%. The main characteristic of irAEs is their unpredictability in terms of time of onset, severity and responsiveness to immunosuppressive agents. Therefore, the management of irAEs often requires clever interpretation of clinical symptoms, proper choice of laboratory tests and imaging tools, and ability to perform differential diagnosis with other condition associated to tumour itself or to unrelated concomitant events (i.e., infections). Although international societies (i.e.; ESMO) have provided detailed guidelines for the management of irAEs or algorithms for the administration of ICI in patients with pre-existing autoimmune disease, they are sometimes difficult to be applied to certain complex situations. Furthermore, given the scarcity of data from clinical trials, some of these recommendations are mainly based on highly heterogeneous patients' population included in relatively small real world studies. Therefore, recommendations should always be adapted to specific clinical conditions and challenges. Studies investigating these aspects have particularly focused on the autoimmune antibody response, correlating its positivity in various ways with clinical outcomes. However, the results across different studies are not consistent. Moreover, additional prospective data are needed to confirm which information can guide the management of irAEs in order to optimize therapy and improve prognosis without negatively impacting oncological outcomes. The adoption of a therapeutic strategy tailored to irAEs is essential for improving both the immunological and oncological prognosis of patients affected by this group of manifestations. A prospective and cross-sectional observational approach to study irAEs is fundamental to the development of such therapeutic innovation. This study approach must be based not only on monitoring patients who have already developed irAEs but also on profiling patients even before the development of irAEs to determine which factors are associated with this group of pathologies and the different characteristics they may assume once they arise. The protocol will be based on the retrospective acquisition of data concerning the clinical history of the patients involved, from birth until recruitment into the study, and the prospective recording of information regarding the disease characteristics (both immuno-rheumatological and oncological) and the subsequent evolution of the clinical picture. Study procedures will take place during visits scheduled as part of routine clinical practice and will include the collection of data-clinical, laboratory, and imaging-related to the patient's oncological disease and irAEs, the characteristics of the diagnostic-therapeutic procedures performed, and the subsequent immuno-oncological outcomes. All patients scheduled to begin immunotherapy treatment will be enrolled in the study, as well as those who have developed irAEs without being enrolled prior to the onset of immuno-mediated manifestations. Enrolled patients who do not develop irAEs will be considered as the control group, providing essential information on risk profiling for the development of irAEs.",[70,27,136,73],"Cancer (Solid Tumors)",[138,139,70,140,141,142,143,144],"Immunotherapy","Adverse Events","Immune-Related Adverse Events","irAEs","PD-1\u002FPD-L1 inhibitors","anti-CTLA-4 agents","ICI","NOT_YET_RECRUITING","2025-09-22",{"date":148,"type":48},"2025-09-30",{"date":150,"type":21},"2025-10-01",{"date":152,"type":21},"2045-09",{"name":154,"class":55},"IRCCS San Raffaele",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":163,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":172,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":192},"100340330","cardiovascular-prevention-strategies-in-elderly-patients-with-cancer-cartier-clinical-trial-100340330","NCT03711110","Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)","Cardiotoxicity in the Elderly. Comparative Clinical Trial Between Primary Versus Secondary Cardiovascular Prevention Strategies","CARTIER","Inclusion Criteria:\n\n* \\> 65 years old\n* Expected survival \\>1 year\n* Colon cancer, breast cancer, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia, myeloma\n* Signature on the informed consent\n\nExclusion Criteria:\n\n* Patients included in clinical trials will be excluded if they interfere with the CARTIER follow-up protocol. If they do not interfere they can be included\n* Patients who had received previous potentially cardiotoxic anticancer treatment","65 Years",{"count":165,"type":21},514,[24],"The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies: primary (intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care) vs. secondary (current clinical practice where intensive cardiovascular monitoring is not routinely performed and cardiotoxicity patient care is based on the onco-hematologist criteria).\n\nThe primary endpoint is to determine whether this primary prevention englobing cardiovascular monitoring plus intensive multidisciplinary management is superior to the current clinical practice in reducing all cause mortality.\n\nOther secondary objectives of the study are to analyze the impact of this intensive cardiovascular monitoring strategy on the incidence of cardiovascular mortality, oncological mortality, hospitalization and\u002For urgent care due to cardiovascular complications, hospitalization and\u002For urgent oncological care due to cancer complications, tumor progression and cost-effectiveness analysis.\n\nA total of 514 patients ≥ 65 years old diagnosed with any of the following onco-hematological cancers, colon, breast, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia or myeloma, undergoing standardized anti-tumoral treatment, will be recruited.\n\nThe incidence of primary and secondary outcomes will be measured at 2 and 5 years",[27,169,170,171],"Elderly","Antineoplastic Agents","Cardiotoxicity",[171,169,173,174,175,176,177,178,179,180,181,182],"Antineoplastic agents","Cardiovascular monitoring","Cardioprotection","Cardio-oncology","Chemically-Induced Disorders","Radiation Injuries","Drug-Related Side Effects and Adverse Reactions.","Primary prevention","Secondary prevention.","Mortality","2025-03-18",{"date":185,"type":48},"2025-03-21",{"date":187,"type":48},"2019-08-02",{"date":189,"type":21},"2025-11-30",{"name":191,"class":55},"Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León",14]